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ABSTRACT
Introduction Tungiasis (sand flea disease or jigger 
infestation) is a neglected tropical disease caused by 
penetration of female sand fleas, Tunga penetrans, in the 
skin. The disease inflicts immense pain and suffering on 
millions of people, particularly children, in Latin America, 
the Caribbean and sub- Saharan Africa. Currently, there is 
no standard treatment for tungiasis, and a simple, safe 
and effective tungiasis treatment option is required. Tea 
tree oil (TTO) has long been used as a parasiticidal agent 
against ectoparasites such as headlice, mites and fleas 
with proven safety and efficacy data. However, current 
data are insufficient to warrant a recommendation for its 
use in tungiasis. This trial aims to generate these data 
by comparing the safety and efficacy of a 5% (v/w) TTO 
proprietary gel formulation with 0.05% (w/v) potassium 
permanganate (KMnO
4) solution for tungiasis treatment.
Methods and analysis This trial is a randomised 
controlled trial (RCT) in primary schools (n=8) in South- 
Western Kenya. The study will include school children 
(n=88) aged 6–15 years with a confirmed diagnosis of 
tungiasis. The participants will be randomised in a 1:1 ratio 
to receive a 3- day two times a day treatment of either 5% 
TTO gel or 0.05% KMnO
4 solution. Two viable embedded 
sandflea lesions per participant will be targeted and the 
viability of these lesions will be followed throughout the 
study using a digital handheld microscope. The primary 
outcome is the proportion of observed viable embedded 
sand fleas that have lost viability (non- viable lesions) by 
day 10 (9 days after first treatment). Secondary outcomes 
include improvement in acute tungiasis morbidities 
assessed using a validated severity score for tungiasis, 
safety assessed through adverse events and product 
acceptability assessed by interviewing the participants to 
rate the treatment in terms of effectiveness, side effects, 
convenience, suitability and overall satisfaction.
Ethics and dissemination The trial protocol has been 
reviewed and approved by the University of Canberra 
Human Research Ethics Committee (HREC-2019-2114). 
The findings of the study will be presented at scientific 
conferences and published in a peer- reviewed journal.
Trial registration numbers Australian New Zealand 
Clinical Trials Registry (ACTRN12619001610123); 
PACTR202003651095100 and U1111-1243-2294.
INTRODUCTION
Tungiasis (sand flea disease or jigger infesta-
tion), is a neglected tropical disease (NTD) 
caused by penetration of an ectoparasite, 
female sand flea, Tunga penetrans.1–3 It is 
rampant in resource- limited communities 
in Latin America, the Caribbean and sub- 
Saharan Africa,2 where children (aged 5–14 
years) and the elderly (≥60 years) are most 
heavily affected, with prevalence data ranging 
Strengths and limitations of this study
 ► Given tungiasis affects the most disadvantaged
communities, this work has an ultimate objective
of reducing the tungiasis burden and improving the
health and well- being of affected children and com-
munities in Kenya.
 ► Educational and community support packages (eg,
health education using flip charts) delivered to the
participating communities as part of this study, will
help facilitate the appropriate control of tungiasis
with sustainable benefits to the community.
 ► If tea tree oil gel effectively treats tungiasis, this
would provide compelling evidence for a simple, af-
fordable and effective treatment for tungiasis, which 
does not require direct supervision by a trained
health worker, essentially enabling the communities
and/or individuals to manage their own health.
 ► Compliance with the treatment protocol is likely to
be less than ideal in the targeted study settings in
Kenya, and we also expect considerable attrition;
however, regular follow- up is likely to improve pa-
tient compliance and limit attrition.
 ► The identity of trial interventions could not be con-
cealed to the study participants and caregivers.
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from 50% to 85%.4–6 No clear estimates of global burden 
of tungiasis exist,7 but according to the WHO, 20 million 
people are estimated to be at risk of developing tungiasis 
in South America alone.8 Based on Kenyan and Ugandan 
Ministries of Health,9 10 about 4 million people suffer 
from the tungiasis, with another 16 million are at risk. A 
tungiasis infected person can harbour up to hundreds of 
parasites, usually on the feet and hands with toes, soles 
and heels are the sites most frequently affected.6 11 The 
infection results in intense inflammation and itching, 
and frequently occurs with secondary bacterial infections, 
resulting in abscesses, suppuration, cellulitis, lymphan-
gitis, sepsis, tetanus and post- streptococcal glomerulone-
phritis. Repeated infection can lead to deformation and 
loss of nails, and disfigurement of the feet.8 12–15 Tungiasis 
negatively impacts education (in children), quality of life, 
household economy and well- being of the affected indi-
viduals.8 9 16–19
Currently, there is no standard treatment for tungi-
asis.19 Parasiticides such as oral thiabendazole,20 oral iver-
mectin21 and topical benzyl benzoate22 and disinfectants 
like hydrogen peroxide,9 have been explored for tungiasis 
treatment, but there is little conclusive evidence available 
on their safety or effectiveness. Our seminal system-
atic review on this topic23 identified eight randomised 
controlled trials (RCTs)24–31 investigated interventions 
for tungiasis. These included: coconut oil- based lotion 
(Zanzarin) for prevention; and oral—niridazole and iver-
mectin; topical—ivermectin lotion, metrifonate lotion, 
thiabendazole lotion, thiabendazole ointment, dimeti-
cones (NYDA) and a neem seed and coconut oils- based 
mixture for treatment. Among these, the coconut oil- 
based lotion for prevention, and dimeticones for treat-
ment of tungiasis displayed the most promise. However, 
the coconut oil- based lotion is no longer commercially 
available and dimeticones are expensive and currently 
not available in tungiasis endemic areas in sub- Saharan 
Africa including Kenya, thus limiting treatment options 
to surgical extraction of embedded fleas and bathing 
feet with 0.05% potassium permanganate (KMnO4) solu-
tion.31 32 In such settings, surgical extraction is frequently 
performed using unsafe procedures involving sharing of 
sharp instruments, leading to additional bacterial super-
infections and potential transmission of viral pathogens 
like HIV, hepatitis B and hepatitis C.12 33 34 Although 
bathing feet with 0.05% KMnO4 solution is widely used 
in Kenya and is recommended by the country’s Ministry 
of Health,9 recent trials25 31 have revealed that it was only 
marginally effective, killing less than 40% of embedded 
fleas.
Thus, there is a critical need for new, safe, effective 
and affordable treatments for tungiasis. This trial aims to 
address this unmet critical need by trialling a novel 5% 
tea tree oil (TTO) gel- based skin formulation. Unlike 
current treatment agents used, TTO possesses a unique 
combination of potent insecticidal, acaricidal, antibacte-
rial, anti- inflammatory and wound healing properties.35 36 
It has long been used as a helpful topical treatment agent 
for a variety of epidermal parasitic skin diseases in 
Australia and Europe, with good safety and efficacy data.37 
The insecticidal and acaricidal effects of topical formu-
lations of TTO for a range of medical ectoparasites/
pests, including house dust mites, Demodex mites, scabies 
mites, ticks, headlice and fleas, have been investigated in 
several in vitro, animal and clinical studies, reporting an 
efficacy range of 70%–100% against these parasites.38–43 
TTO is also effective at low concentrations (in vitro) as 
a bactericide (at 0.002%–2%; including against MRSA 
(methicillin- resistant Staphylococcus aureus)), and as an 
anti- inflammatory agent (≤0.125%).36 In sum, an ideal 
therapeutic candidate for tungiasis should be able to kill 
the embedded parasite, prevent inflammatory skin reac-
tions and block bacterial infection. The unique parasit-
icidal, antibacterial and anti- inflammatory properties of 
TTO appear to hold tremendous potential in reducing 
the burden of tungiasis and its deadly sequalae. The aim 
of this RCT is to investigate the safety and efficacy of a 
5% v/w TTO- proprietary gel formulation in comparison 
with the locally endorsed, 0.05% w/v KMnO4 solution for 
tungiasis treatment in children.
METHODS AND ANALYSIS
This protocol has been written in line with the Standard 
Protocol Items: Recommendations for Interventional 
Trials guidelines (online supplemental file 1).44
Study setting and design overview
The study will be conducted at eight selected primary 
schools (permission letters obtained from the respec-
tive directors of the schools) in Kisii and Nyamira coun-
ties, South- Western Kenya where tungiasis is endemic.9 
Schools have been selected based on the presence of 
students with tungiasis and willingness of the principals 
to collaborate in the study. Schools already have strong 
collaborative working relationships with our community 
collaborator, Global School Partners (GSP), a local non- 
government and not- for- profit charity organisation in 
Kenya (GSP).45 This pre- existing network of the GSP with 
school directors and student parents will be used to facil-
itate the successful completion of this study.
The study is designed as an assessor- blinded, phase II 
RCT. It will be conducted in the dry season as tungiasis 
peaks during this period.14 Eighty- eight participants with 
tungiasis will be recruited and randomised in a 1:1 ratio 
to receive either the 5% TTO proprietary gel formula-
tion or 0.05% KMnO4 solution. TTO- gel is a water- based, 
transparent, skin formulation with excellent spreading 
properties and pleasing aesthetic characteristics. It 
contains 5% v/w pure and standard Australian TTO (ISO 
4730:2017 and AS 2782:2017), approximately 14% polox-
amer 407 gel, and other excipients such as formulation 
stabilisers, penetration enhancers and preservatives. 
It will be prepared following the WHO’s current Good 
Manufacturing Practice (Institute of Drug Technology, 
Australia). KMnO4 solution contains 0.05 g KMnO4 in 
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a litre of water. The selection of KMnO4 solution as the 
active comparator in this study reflects its status as a local 
tungiasis treatment used in mass campaigns in children 
(and adults) in Kenya,46 and its being the recommended 
tungiasis treatment by the Kenyan Ministry of Health.9 
Study participants’ feet will be fully assessed as more 
than 95% of embedded sand flea lesions are localised to 
this site (toes, soles and heels),6 7 47 with lesions staged 
according to Fortaleza classification system (online 
supplemental file 2).48 The test and control interventions 
will then be applied two times a day on days 1, 4 and 7. 
These treatment days are selected based on the lifecycle 
of the embedded sand flea. As a sand flea can take up to 
1–2 weeks to develop from stage II/III (viable embedded 
lesions) to stage IV (dying or dead embedded sand 
flea),28 48 the use of the three treatment doses is designed 
to ensure that any stage II or III embedded sand flea 
lesion would be killed by the treatments before they die 
due to their natural course. After the treatment, viability 
signs of embedded fleas in each participant will be moni-
tored. The proportion of observed viable embedded sand 
fleas that have lost viability (non- viable lesions) by day 
10 will be determined and compared between test and 
control groups, as the primary outcome.
Study personnel
The trial will be conducted by a recruitment team and a 
study team in each school. These teams will be composed 
of staff members of GSP.45 The recruitment team will 
consist of school nurses led by a recruitment officer. This 
team will be responsible for liaising with the school direc-
tors and caregivers to facilitate the participants’ informed 
consent and allocation procedures. The school directors 
will be used as mediators to reach out to caregivers and 
potential participants. The members of the team will 
receive information and training about the trial particu-
larly the recruitment procedure.
The study team will comprise clinical advisors and 
clinical assessors, led by one of the clinical advisors. 
The clinical advisors are experienced medical doctors 
working in hospitals located in the study areas. The clin-
ical assessors are school nurses who will be responsible 
for collecting baseline demographic and disease charac-
teristics, treating participants and performing outcome 
assessments. They will be trained on the overall trial and 
outcome assessment (viability assessment and staging of 
the embedded sand fleas), intervention application and 
safety monitoring procedures. The clinical advisors will 
supervise the clinical assessors, particularly in outcome 
assessment procedures, and be consulted in any case of 
diagnostic uncertainty. The reports of clinical assessors 
will further be evaluated by a panel of infectious disease 
specialists or offsite clinical assessors by evaluating the 
photograph records of each participant.
Sample size calculation
The sample size calculation is based on the primary 
outcome measure, assuming the 0.05% KMnO4 solution 
will have a 40% efficacy,25 and the 5% TTO proprietary 
gel formulation will have a 70% efficacy at 10 days. There 
are no reports of clinical trials exploring TTO proprietary 
gel formulation for tungiasis treatment. Hence, the effi-
cacy of TTO was estimated based on the existing obser-
vational studies on tungiasis, the clinical experience of 
our team members, findings from similar trials exploring 
other tungiasis treatments and findings of studies (in 
vitro and in vivo) on TTO against other ectoparasites. To 
enable the detection of this 30% difference with at least 
80% power at a significance level of 5%, a sample size of 
40 participants per arm (88 in total accounting for 10% 
attrition, as seen in similar settings27) is required.
Study participants
The study population will consist of school children aged 
6–15 years from eight schools with a confirmed diagnosis 
of tungiasis. The age range of 6–15 years was selected 
because tungiasis is highly prevalent in this group.49 50
Consent and assent
Before starting the study, face- to- face meetings with care-
givers, participants and school directors will be held to 
explain the objectives of the research and to facilitate an 
understanding of how the research aligns with commu-
nity values. The overall procedure of the study, the nature 
of the disease, the preventive strategies, details of the 
treatments and risks and benefits of participation will 
also be explained to caregivers and participants using 
instruction manuals containing coloured photographic 
images to ensure they fully understand the consequences 
of participation. A pictorial consent flipchart will be used 
and any study documents including information booklet 
will be translated into the locally spoken language to assist 
and facilitate the consent process. After this explanation, 
the participant’s legally responsible caregiver/parent will 
be provided a participant information sheet and asked 
to complete an informed consent with written assent (if 
aged 12–15 years) or verbal assent (if aged 6–11 years) 
provided by children (online supplemental files 3 and 
4). If a subject and his/her caregiver are unable to read, 
an impartial witness must be present during the entire 
informed consent discussion. The signature of the impar-
tial witness will certify the subject’s consent. The partic-
ipant’s parent/caregiver will receive a signed and dated 
copy of the consent form.
Recruitment and enrolment
Potential participants with tungiasis will be identified 
in each school and recruited by the recruitment team 
over 3 months. Eligibility assessment (presence of viable 
embedded sand fleas) will be initiated by the clinical asses-
sors under the supervision of the clinical advisor as per 
the inclusion and exclusion criteria. If a potential partic-
ipant meets the study criteria, he or she will be invited to 
a room designated for study procedures, referred to as a 
study centre, for further examination.
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Participants’ must have at least one viable embedded 
sand flea lesion (stage II or stage III) as inclusion crite-
rium. Viable embedded sand flea lesions located at the tip 
of toes, soles and rim of heels will be exclusively selected 
for this purpose.
Participants’ exclusion criteria are (1) participants with 
cluster lesions (≥3 together) or manipulated lesions; (2) 
the presence of complicated sand flea lesions requiring 
antibiotic treatment (these children will be referred to 
nearby health facilities for appropriate management); 
(3) evidence that guardian/parent/caregiver intend to
change their place of residence during the study period;
(4) known history of allergy to any of the study medica-
tions (TTO or other essential oils and/or KMnO4) and
(5) the use of systemic or topical drugs or medications,
particularly antibiotics, which may interfere with the
study results.
Eligible participants will be instructed to come back to 
the study centre located in each school for randomisa-
tion, baseline assessment, treatment and outcome assess-
ments. An outline of the recruitment and enrolment 
process with study timeline is given in figure 1.
Randomisation and treatment allocation
Participants will be allocated to either the test (5% TTO 
gel) or control (0.05% KMnO4 solution) group in a 1:1 
ratio using a predetermined, computer- generated rando-
misation schedule developed by an independent statis-
tician who will not be directly involved in the study. All 
participants in each school will be allocated in the study 
with participant from new schools included to the study 
until the minimum sample is reached. The randomisa-
tion schedule will be kept secure (password- protected) 
by the statistician. The randomisation schedule will be 
concealed from trial participants, clinical assessors and 
data assessors (who will be analysing the data) until the 
participants have been assigned into the trial.
Blinding
Foot bathing with the KMnO4 solution may change the 
colour of the skin to dark purple. As a result, the trial 
participants and onsite clinical assessors cannot be 
blinded to the trial interventions. However, a blind assess-
ment of photographs of tungiasis lesions by an expert 
panel of clinicians (offsite clinical assessors) during the 
data analysis phase will prevent any likelihood of investi-
gator bias in the outcome assessments. To keep the offsite 
clinical assessors and data assessors blind, they will not 
be involved in the clinical trial procedures or have any 
contact with trial participants. Given the primary efficacy 
outcome will be measured 3 days after the last treatment, 
we do not consider that the colour of KMnO4 solution on 
the feet would compromise the blinding of offsite clin-
ical assessors. The onsite team will carefully assess the skin 
surrounding the targeted lesions and ensure the absence 
of any trace of purple staining prior to taking the photo-
graphs. In any case that the blinding is broken, the study 
team will document the date and reason for breaking.
Study participant treatment
The randomised participants will receive either the test 
(5% TTO- proprietary gel formulation) or control (0.05% 
KMnO4 solution) intervention. They will be required to 
attend the study centre in each school two times a day 
(AM and PM) on days 1, 4 and 7 for the treatments. At 
each visit the feet of the participants will be washed with 
water and soap, dried with a clean towel and toenails 
clipped as necessary to enable the easier application of 
the products. The allocated treatments will be applied 
by the clinical assessors. The test product will be applied 
by smearing the required amount (up to 8 g/day) of 
the product on the palms and spreading it over the skin 
surface of the feet up to the ankle including the soles, and 
interdigital areas (between toes). The treated feet will 
then be left for about 15 min to allow the test products to 
dry. In contrast, the comparator product will be applied 
by immersing and bathing the feet up to the ankle in a 
bucket containing a 0.05% KMnO4 solution (up to 2.5 
L) for 15 min. After sun drying the feet, a thin layer of
petroleum jelly, fully covering the treated surface, will be
applied for the purpose of softening the roughness on
the skin caused by the KMnO4 treatment.
After the initial treatment (day 1 AM), all participants 
will be given pairs of closed shoes to be worn throughout 
the study period and to be kept after the study participa-
tion. This will help the treatments remain on the feet and 
protect the feet from contamination with dirt and water. 
Also, wearing closed shoes may decrease reinfestation. 
Participants will be advised to avoid using or mixing any 
other tungiasis treatments with trial medications during 
the study period. They will also be advised at each visit to 
regularly wear the provided pair of shoes throughout the 
study period. Dates and times of start and end of treat-
ment application, as well as any non- compliance with the 
trial protocol will be documented in the case report form 
(CRF, online supplemental file 5).
Outcome assessment
Primary outcome
The primary and secondary efficacy end points are the 
proportion of observed viable embedded sand fleas that 
have lost viability (non- viable lesions) by day 10 (9 days 
after first treatment) and by day 5 (4 days after the first 
treatment), respectively. Participants will be required to 
attend the study centre in each school once daily (AM or 
PM) at baseline, days 5 and 10 for the outcome assessment. 
At baseline, viability of the embedded sand flea lesions 
located in the feet will be assessed using a handheld digital 
video microscope, assisted with pictorial flipcharts. Sites of 
all viable (stage II–III) lesions will be recorded on the foot 
diagram sheets and the entire feet and appearance will be 
photographed to document the baseline characteristics 
of the embedded sandflea lesions. Two viable embedded 
sand flea lesions will be selected as target lesions and 
will then be observed for their viability at each outcome 
assessment visit. All the information collected at baseline, 
such as the number of viable embedded sand flea lesions, 
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non- viable lesions, manipulated lesions, severity score for 
acute tungiasis morbidities (SSAT), itching, pain, and 
pain- related and itching- related sleep disturbance, will be 
documented and recorded in each participant’s CRF. The 
photographs will also be linked to the participant’s CRF. 
At each follow- up visit, the entire feet of participants will 
also be thoroughly examined and the two target lesions 
per participant selected during baseline assessment, 
will be observed for their viability on days 5 and 10. The 
number of target lesions that become non- viable after the 
Figure 1 Overview of the study process. *BID, two times a day. TTO, tea tree oil.
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interventions will be recorded for each study participant 
at each follow- up visit. Photographs will be recorded and 
reviewed during the analysis phase to confirm observa-
tions recorded in the CRF.
A panel of blinded offsite clinical assessors will eval-
uate photographs of the targeted embedded sand flea 
lesions taken at baseline, days 5 and 10 independently 
of the onsite clinical assessors and the primary outcome 
measure will be determined by the blinded photograph 
assessment of the offsite clinical assessor. Any discrepancy 
in the assessment results will be adjudicated by a third 
person. An empirical evaluation of the onsite versus offsite 
agreement will be performed using the kappa coefficient 
to determine reliability of the assessment. To evaluate the 
efficacy of the test intervention, the proportions of non- 
viable lesions in the test group will be compared with the 
control groups at day 10.
Secondary outcomes
The secondary outcomes are SSAT, itching, pain, pain- 
related and itching- related sleep disturbance, safety and 
participant acceptability of the trial intervention/s. The 
SSAT, which includes typical signs of local inflammation 
(erythema, oedema and warmness) and the presence 
of suppuration, ulcers and fissures, will be evaluated by 
the clinical assessors at baseline, days 5 and 10, using a 
validated scoring system designed for tungiasis morbidity 
assessment.51 The entire feet and appearance will be 
photographed and recorded in the CRF to evaluate this 
outcome measure. The itch- man scale for itching,52 and 
4- point tungiasis pictorial scales18 for pain, and pain and
itching- related sleep disturbance will be used to evaluate
these outcomes.
Safety will be assessed through adverse events (AEs) 
and evaluations of the skin irritation during each visit 
(days 1, 4, 5, 7 and 10). Participants/caregivers (in- person 
or on the phone) will be asked at each follow- up visit by 
the study team about the occurrence of local (stinging/
burning, irritation and itching) or systemic AEs (nausea 
and headache). Children will be physically examined 
for evidence of local swelling, erythema and fever. The 
severity of the AEs will be categorised as mild (grade 1), 
moderate (grade 2), severe (grade 3) and life- threatening 
(grade 4) according to the Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0 guide-
line (online supplemental file 2).53 Acceptability of the 
treatments will be assessed at the end of the study (day 10) 
by asking the participants to rate the treatment in terms 
of effectiveness, side effects, convenience, suitability and 
overall satisfaction. Responses to these questions will be 
recorded in the CRF.
Adherence and retention
Continuous motivation and advice will be given by the clin-
ical assessors to the participants at each visit throughout 
the study to promote study retention. Participants and/
or carers will also be asked to complete a treatment diary 
recording the daily progression of the condition—which 
will reinforce the need for optimum treatment compli-
ance. Community home visits will be organised, if 
required (eg, in case of absenteeism from school).
Monitoring and reporting of AEs
If AEs occur, the clinical advisors will determine the rela-
tionship between the AEs and the trial medication. AEs 
considered related to the trial medication will be followed 
up until either resolution, or the event is considered 
stable. All grade 1 and 2 AEs reported spontaneously by 
the subject or observed by the study team will be recorded 
in the AE form and documented in each participant’s 
CRF. The following information about each AE will also 
be recorded where available: description, onset and end 
date, severity, expectedness, assessment of relatedness to 
trial medication, what action was taken afterwards and 
whether the participant was withdrawn from the trial.
A serious AEs (SAEs) will also be reported to the 
Human Ethics Committees and regulatory bodies as per 
the reporting schedule stipulated in their guidelines. 
The following information will be documented in the 
SAE form: description, classification, start date, status/
outcome, relatedness to study intervention, therapy given 
and any actions taken to study intervention.
Statistical analysis
All data will be reported following the Consolidated 
Standards of Reporting Trials guidelines (online supple-
mental file 6).54 A detailed analysis plan will be approved 
by all investigators before any data analysis. The data will 
be analysed by the study statistician who will be blinded 
to the treatment allocation. Statistical analyses will be 
performed for both the intention to treat (ITT) and 
per- protocol (PP) populations. The ITT population will 
include all randomised participants treated or not, and 
any participants who withdraw prematurely or poorly 
comply with the protocol. The PP population will be all 
subjects who are enrolled in the study, randomly assigned 
to the treatment regimen, received three doses (two times 
a day) and do not deviate from the study protocol in a 
clinically significant manner. Results will be considered 
significant if p≤0.05.
Baseline characteristics collected on each patient will 
be reported and compared between randomisation 
groups including age, sex, number of viable embedded 
sand flea lesions, SSAT, as well as scores for pain, itching 
and sleep disturbance. Categorical (qualitative) variables 
will be summarised by frequency and percentage. Contin-
uous variables will be summarised as mean and SD in case 
of normal distribution and as median and IQR in case 
of non- normal distribution. The Shapiro- Wilk test will be 
used to assess the normality of the distribution of outcome 
variables for both groups. Independent Student’s t- test or 
Mann- Whitney tests will be used to investigate differences 
in continuous variables, and χ2 tests will be used to iden-
tify significant variations in proportions across treatment 
groups.
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Based on the change in primary outcome, the efficacy 
of test and comparator products will be compared at 
each follow- up visit. The difference in proportion of non- 
viable lesions between the test and control groups will be 
compared using Student’s t- test or Mann- Whitney tests 
depending on the distribution and presented as relative 
and absolute risk reductions with their respective 95% 
CIs and p values. Further, within- group differences will 
be assessed using paired t- test in case of normally distrib-
uted data and a Wilcoxon signed- rank test in case of non- 
normally distributed data. Secondary outcomes will be 
compared in the same fashion as the primary outcome.
Study management
Quality assurance audits of the clinical trial and related 
documentation will be performed during and after this 
study in accordance with the International Conference 
on Harmonisation Good Clinical Practice (ICH- GCP) 
guidelines and recommendations.55 56 The quality assur-
ance will also consider the Kenyan GCP guideline and 
the Pharmacy and Poisons Board (PPB) requirements. 
Trial standard operating procedures (SOPs) will be used 
to ensure that the trial will be conducted, and data are 
generated, documented (recorded) and reported in 
compliance with the latest approved protocol, ICH- 
GCP, Declaration of Helsinki, Kenyan GCP, PPB and 
National Commission for Science Technology and Inno-
vation (NACOSTI) requirements. The data monitoring 
committee will involve a medical practitioner, toxicologist 
and pharmacist.
Patient and public involvement
Patients and/or the public will not involve in the study 
design, conduct, reporting or dissemination plans of 
this research. Study results and feedback will be dissem-
inated to patients by local trial team in formats that are 
useful and understandable, such as community meetings, 
presentations, websites and social media.
ETHICS AND DISSEMINATION
Ethical approval
The trial protocol has been approved on 29 August 2019 
by the University of Canberra Human Research Ethics 
Committee (HREC20192114) and registered with WHO 
accredited registries (online supplemental files 7–9). 
Further, the investigators will secure ethical approvals 
from one of the NACOSTI (Kenya) accredited ethics 
review committees and will seek letters of support from 
both the Kenyan Ministry of Health and Ministry of 
Education.
Confidentiality and access to data
The privacy of participants will be protected by appro-
priate collection and storage of data. Participants 
will be identified only by initials and participant ID 
numbers on the CRFs and in any electronic databases. 
Data collection forms will be stored in locked filing 
cabinets in a locked office at the participating schools 
until the end of the study period, which will then be 
transferred to the University of Canberra and handled 
as per the university’s recommended data storage 
guideline for clinical trials. All documents will only be 
accessible by trial staff and authorised personnel. Docu-
ments containing participant’s identifying information 
will not be stored electronically and will be anonymised 
as soon as practical. Participants will be advised their 
records may be examined by lawful authorities but will 
be treated with strict confidentiality and will not be 
made publicly available.
Dissemination
Study results and feedback will be disseminated to end- 
users (participants and community members, counties’ 
health bureaus and other relevant government organi-
sations) in formats that are useful and understandable, 
such as community meetings, presentations, websites, 
social media and radio announcements. The findings 
of this study will also be disseminated through peer- 
reviewed journals and national and international scien-
tific meetings.
DISCUSSION
In endemic communities, tungiasis morbidity is caused 
by the parasite and associated inflammatory skin 
reactions and secondary bacterial infections. Thus, 
proposed treatment options should have the potential 
to address the morbidities caused by the parasite and 
treat secondary bacterial complications. In this vein, 
TTO is a strong fit for tungiasis treatment as it possesses 
a unique combination of parasiticidal, antibacterial, 
anti- inflammatory and wound healing properties.36 
There has been a claim that TTO causes skin irritation 
or allergic contact dermatitis.57 In a suitable pharma-
ceutical base at concentrations ≤25%, multiple clinical 
studies58–64 have shown that TTO has no or low risk of 
adverse skin reactions. While potential toxicity in chil-
dren is yet to be extensively evaluated, a report from an 
RCT65 in children (mean age 6.3+5.1 years) with viral 
molluscum contagiosum demonstrated that 75% (v/v) 
TTO was well tolerated in the 30- day treatment period. 
TTO’s sensitising potential is largely due to elevated 
levels of peroxides and other degradation products 
from oxidised oil.66 When correctly stored in amber 
glass bottles with polypropylene caps, TTO has no 
appreciable degradation for up to 12 months.36 57 Due 
to its high volatility, 90% of the applied TTO rapidly 
evaporates, minimising the potential for components 
to permeate the dermis and bloodstream. Nevertheless, 
key active components (terpinen-4- ol, α-terpineol and 
1,8- cineole) have sufficient epidermal penetration to 
provide antimicrobial, anti- inflammatory and poten-
tially insecticidal and acaricidal effects.35
If TTO gel effectively treats tungiasis, this trial will 
provide compelling evidence for a simple, affordable and 
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effective treatment for disadvantaged populations with a 
significant health burden. This will lead to a significant 
change in the treatment of this neglected condition. 
While the tungiasis- affected children in selected Kenyan 
villages are intended as the primary beneficiaries of this 
research, the pattern of tungiasis and associated bacte-
rial complications among children is analogous to that 
observed in resource- poor and underprivileged endemic 
communities in many parts of the world, especially in sub- 
Saharan Africa. Thus, the results from this study have the 
potential to provide evidence for a global health role of 
TTO in managing tungiasis and its associated complica-
tions in children.
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